Characterization of proteome of human cerebrospinal fluid.

[1]  F. Marshall.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. , 2005, The Journal of urology.

[2]  T. Montine,et al.  The FASEB Journal express article 10.1096/fj.04-3210fje. Published online March 3, 2005. ©2005 FASEB , 2022 .

[3]  P. Lockhart,et al.  Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. , 2005, Brain research. Molecular brain research.

[4]  D. Desiderio,et al.  Proteomics analysis of prefractionated human lumbar cerebrospinal fluid , 2005, Proteomics.

[5]  Jing Zhang,et al.  Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid , 2005, Neurobiology of Aging.

[6]  Baruch S Blumberg,et al.  Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Shiraishi,et al.  Combined proteomic approach with SELDI-TOF-MS and peptide mass fingerprinting identified the rapid increase of monomeric transthyretin in rat cerebrospinal fluid after transient focal cerebral ischemia. , 2004, Brain research. Molecular brain research.

[8]  Kelvin H. Lee,et al.  Affinity depletion of albumin from human cerebrospinal fluid using Cibacron-blue-3G-A-derivatized photopatterned copolymer in a microfluidic device. , 2004, Analytical biochemistry.

[9]  Ruedi Aebersold,et al.  Analysis of α-Synuclein-associated Proteins by Quantitative Proteomics*[boxs] , 2004, Journal of Biological Chemistry.

[10]  M. Deeg,et al.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients , 2004, Laboratory Investigation.

[11]  Ruedi Aebersold,et al.  The Need for Guidelines in Publication of Peptide and Protein Identification Data , 2004, Molecular & Cellular Proteomics.

[12]  T. Buschmann,et al.  Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. , 2004, Pathology, research and practice.

[13]  R. Bischoff,et al.  Methodological advances in the discovery of protein and peptide disease markers. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[14]  Lin He,et al.  Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. , 2004, Journal of chromatography. A.

[15]  Ruedi Aebersold,et al.  A microcapillary trap cartridge-microcapillary high-performance liquid chromatography electrospray ionization emitter device capable of peptide tandem mass spectrometry at the attomole level on an ion trap mass spectrometer with automated routine operation. , 2003, Rapid communications in mass spectrometry : RCM.

[16]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[17]  Ruedi Aebersold,et al.  Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry , 2003, Nature Biotechnology.

[18]  S. McCutchen-Maloney,et al.  Characterization of transcription factors by mass spectrometry and the role of SELDI-MS. , 2002, Mass spectrometry reviews.

[19]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[20]  R. Aebersold,et al.  Approaching complete peroxisome characterization by gas‐phase fractionation , 2002, Electrophoresis.

[21]  T. Yip,et al.  SELDI ProteinChip® Array in Oncoproteomic Research , 2002, Technology in cancer research & treatment.

[22]  D. Hochstrasser,et al.  Proteomics and its trends facing nature's complexity , 2002, Proteomics.

[23]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[24]  D. Desiderio,et al.  Analysis of the human lumbar cerebrospinal fluid proteome , 2002, Electrophoresis.

[25]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[26]  R. Aebersold,et al.  Mass spectrometry in proteomics. , 2001, Chemical reviews.

[27]  D. Hochstrasser,et al.  The dynamic range of protein expression: A challenge for proteomic research , 2000, Electrophoresis.

[28]  J. Jankovic,et al.  The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. , 2000, Archives of neurology.

[29]  J. Yates,et al.  Direct analysis of protein complexes using mass spectrometry , 1999, Nature Biotechnology.

[30]  K. Jellinger,et al.  Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. , 1998, Archives of neurology.

[31]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[32]  J. Yates,et al.  Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. , 1995, Analytical chemistry.

[33]  J. Stevens,et al.  Post‐lumbar puncture headaches , 1992, Neurology.

[34]  B. Chait,et al.  Weighing naked proteins: practical, high-accuracy mass measurement of peptides and proteins. , 1992, Science.

[35]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[36]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[37]  A. Rajput,et al.  Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[38]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[39]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[40]  Jing Zhang,et al.  Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.

[41]  A. Legrand,et al.  A Sensitive Time-Resolved Immunofluorometric Assay for the Measurement of Apolipoprotein B in Cerebrospinal Fluid. Application to Multiple Sclerosis and Other Neurological Diseases , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[42]  K. Blennow,et al.  Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. , 1993, European neurology.

[43]  K. Blennow,et al.  Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. , 1993, European neurology.

[44]  K. Blennow,et al.  Protein Analysis in Cerebrospinal Fluid , 1993 .